Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Assenat

Showing results (121-130 of 153) with videos related to

Pageof 16
Sort By:
Journal of Clinical Medicine|February 11, 2023
Stereotactic MR-Guided Radiotherapy for Liver Metastases: First Results of the Montpellier Prospective Registry StudyKarl Bordeau, Morgan Michalet, Aïcha Keskes, et al.
The Lancet. Oncology|February 5, 2023
Bevacizumab plus FOLFIRI after failure of platinum-etoposide first-line chemotherapy in patients with advanced neuroendocrine carcinoma (PRODIGE 41-BEVANEC): a randomised, multicentre, non-comparative, open-label, phase 2 trialThomas Walter, Astrid Lievre, Romain Coriat, et al.
The Lancet. Gastroenterology & Hepatology|June 22, 2026
Addition of ipilimumab to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (PRODIGE 81-FFCD 2101-TRIPLET HCC): phase 2 results from a randomised, multicentre, open-label, phase 2-3 trialPhilippe Merle, Jean-Frederic Blanc, Karine Le Malicot, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 4, 2025
Neoadjuvant FOLF(IRIN)OX Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Multicenter Randomized Noncomparative Phase II Trial (PANACHE01 FRENCH08 PRODIGE48 study)Lilian Schwarz, Jean-Baptiste Bachet, Aurelia Meurisse, et al.
British Journal of Cancer|January 7, 2022
Chemotherapy (doublet or triplet) plus targeted therapy by RAS status as conversion therapy in colorectal cancer patients with initially unresectable liver-only metastases. The UNICANCER PRODIGE-14 randomised clinical trialMarc Ychou, Michel Rivoire, Simon Thezenas, et al.
The New England Journal of Medicine|May 13, 2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancerThierry Conroy, Françoise Desseigne, Marc Ychou, et al.
Liver Cancer|December 15, 2025
Cabozantinib for Hepatocellular Carcinoma in Real-World Practice (CLERANCE): A Prospective, Interventional StudyFrançois Villeret, Mohamed Bouattour, Jean-Frédéric Blanc, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|April 13, 2020
Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib in REACH and REACH-2Masatoshi Kudo, Peter R Galle, Josep M Llovet, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|December 21, 2017
Evaluating bevacizumab in combination with FOLFIRI after the failure of platinum-etoposide regimen in patients with advanced poorly differentiated neuroendocrine carcinoma: The PRODIGE 41-BEVANEC randomized phase II studyThomas Walter, David Malka, Olivia Hentic, et al.
Ebiomedicine|December 27, 2019
The oncogenic and druggable hPG80 (Progastrin) is overexpressed in multiple cancers and detected in the blood of patientsBenoit You, Frédéric Mercier, Eric Assenat, et al.
Pageof 16

Showing results (121-130 of 153) with videos related to

Sort By:
Pageof 16
Journal of Clinical Medicine|February 11, 2023
Stereotactic MR-Guided Radiotherapy for Liver Metastases: First Results of the Montpellier Prospective Registry StudyKarl Bordeau, Morgan Michalet, Aïcha Keskes, et al.
The Lancet. Oncology|February 5, 2023
Bevacizumab plus FOLFIRI after failure of platinum-etoposide first-line chemotherapy in patients with advanced neuroendocrine carcinoma (PRODIGE 41-BEVANEC): a randomised, multicentre, non-comparative, open-label, phase 2 trialThomas Walter, Astrid Lievre, Romain Coriat, et al.
The Lancet. Gastroenterology & Hepatology|June 22, 2026
Addition of ipilimumab to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (PRODIGE 81-FFCD 2101-TRIPLET HCC): phase 2 results from a randomised, multicentre, open-label, phase 2-3 trialPhilippe Merle, Jean-Frederic Blanc, Karine Le Malicot, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 4, 2025
Neoadjuvant FOLF(IRIN)OX Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Multicenter Randomized Noncomparative Phase II Trial (PANACHE01 FRENCH08 PRODIGE48 study)Lilian Schwarz, Jean-Baptiste Bachet, Aurelia Meurisse, et al.
British Journal of Cancer|January 7, 2022
Chemotherapy (doublet or triplet) plus targeted therapy by RAS status as conversion therapy in colorectal cancer patients with initially unresectable liver-only metastases. The UNICANCER PRODIGE-14 randomised clinical trialMarc Ychou, Michel Rivoire, Simon Thezenas, et al.
The New England Journal of Medicine|May 13, 2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancerThierry Conroy, Françoise Desseigne, Marc Ychou, et al.
Liver Cancer|December 15, 2025
Cabozantinib for Hepatocellular Carcinoma in Real-World Practice (CLERANCE): A Prospective, Interventional StudyFrançois Villeret, Mohamed Bouattour, Jean-Frédéric Blanc, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|April 13, 2020
Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib in REACH and REACH-2Masatoshi Kudo, Peter R Galle, Josep M Llovet, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|December 21, 2017
Evaluating bevacizumab in combination with FOLFIRI after the failure of platinum-etoposide regimen in patients with advanced poorly differentiated neuroendocrine carcinoma: The PRODIGE 41-BEVANEC randomized phase II studyThomas Walter, David Malka, Olivia Hentic, et al.
Ebiomedicine|December 27, 2019
The oncogenic and druggable hPG80 (Progastrin) is overexpressed in multiple cancers and detected in the blood of patientsBenoit You, Frédéric Mercier, Eric Assenat, et al.
Pageof 16